Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. New Aspects of the Kidney in the Regulation of Fibroblast Growth Factor 23 (FGF23) and Mineral Homeostasis

    Research output: Contribution to journalReviewResearchpeer-review

  2. Age-Associated Salivary MicroRNA Biomarkers for Oculopharyngeal Muscular Dystrophy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know

    Research output: Contribution to journalReviewResearchpeer-review

  4. Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo

    Research output: Contribution to journalReviewResearchpeer-review

  1. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prognostic utility of serum YKL-40 in patients with cervical cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Triage May Improve Selection to Colonoscopy and Reduce the Number of Unnecessary Colonoscopies

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

In this study we investigated the use of cancer cell protein expression of ABCG2 to predict efficacy of systemic first-line irinotecan containing therapy in patients with metastatic colorectal cancer (mCRC). From a Danish national cohort, we identified 119 mCRC patients treated with irinotecan containing therapy in first-line setting. Among these, 108 were eligible for analyses. Immunohistochemistry (IHC) analyses were performed on the primary tumor tissue in order to classify samples as high or low presence of ABCG2 protein. Data were then associated with patient outcome (objective response (OR), progression free survival (PFS) and overall survival (OS)). ABCG2 protein expression in the basolateral membrane was high (score 3+) in 33% of the patients. Exploratory analyses revealed a significant interaction between ABCG2 score, adjuvant treatment and OR (p = 0.041) in the 101 patients with evaluable disease. Patients with low ABCG2 (score 0-2) and no prior adjuvant therapy had a significantly higher odds ratio of 5.6 (Confidence Interval (CI) 1.68-18.7; p = 0.005) for obtaining OR. In contrast, no significant associations between ABCG2 expression and PFS or OS were found. These results suggest that measurement of the ABCG2 drug efflux pump might be used to select patients with mCRC for irinotecan treatment. However, additional studies are warranted before conclusions regarding a clinical use can be made. Moreover, patients with high ABCG2 immunoreactivity could be candidates for specific ABCG2 inhibition treatment in combination with irinotecan.

Original languageEnglish
Article number5027
JournalInternational Journal of Molecular Sciences
Volume21
Issue number14
Pages (from-to)1-13
Number of pages13
ISSN1661-6596
DOIs
Publication statusPublished - 16 Jul 2020

    Research areas

  • ABCG2 protein, BCRP, Biomarker, Colorectal cancer, Irinotecan

ID: 60682236